Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Breye Therapeutics raises €67.5 million in Series A led by Mission BioCapital and Novo Holdings to advance oral retinal disease treatments into Phase II trials.
Pappas CapitalModi VenturesCatalyze CapitalEifoInnovestor Life ScienceLjungström family officeSound BioventuresNovo HoldingsMission BioCapital
Description
Breye Therapeutics, a clinical-stage biopharmaceutical company, successfully closed an over-subscribed €67.5 million Series A financing round co-led by Mission BioCapital and Novo Holdings. The round included participation from Sound Bioventures, the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures, and Pappas Capital. Proceeds will fund advancement of danegaptide, a first-in-class oral treatment for Non-Proliferative Diabetic Retinopathy, into a Phase II clinical trial starting in 2027. The financing will also support development of the company's wider pipeline for retinal diseases, including a P2X7 receptor antagonist for intermediate age-related macular degeneration.
Company Information
Company
Breye Therapeutics
Location
Copenhagen, Capital Region Of Denmark, Denmark
About
Breye Therapeutics is a clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases. The company's lead asset, danegaptide, is a first-in-class oral small molecule treatment for Non-Proliferative Diabetic Retinopathy (NPDR) that stabilizes the retinal vasculature. Breye is also advancing a pipeline of assets for retinal diseases, including a P2X7 receptor antagonist for intermediate age-related macular degeneration (iAMD). The company aims to bring patient-friendly treatment options to those living with debilitating eye diseases.
Fundz sees it the moment Breye Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CopenhagenBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma